Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03578224 · ClinicalTrials.gov registry record · Early Phase 1
Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
NCT03578224 is a Early Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 35 participants.
The verdict
NCT03578224, a Early Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This pilot trial studies how well an ultrasound with a contrast agent (perflubutane microbubble \[Sonazoid\]) works in identifying sentinel lymph nodes in participants with esophageal cancer. Sentinel lymph nodes are lymph nodes to which the cancer is likely to spread from the primary tumor. Diagnostic procedures, such as contrast-enhanced ultrasound, may work better in identifying sentinel lymph nodes and finding out how far the disease has spread.
Interventions
- PROCEDURE Contrast-Enhanced Ultrasound
- PROCEDURE Fine-Needle Aspiration
- PROCEDURE Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)
- DRUG Sonazoid (Perflubutane)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2022-08-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03578224
The ClinicalTrials.gov registry entry for NCT03578224 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Contrast-Enhanced Ultrasound is the first listed.
NCT03578224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03578224 about?
NCT03578224 is a clinical study titled "Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer". This pilot trial studies how well an ultrasound with a contrast agent (perflubutane microbubble \[Sonazoid\]) works in identifying sentinel lymph nodes in participants with esophageal cancer. Sentinel lymph nodes are lymph nodes to which the cancer is likely to spread from the primary tumor. Diagnos...
What is the current status of trial NCT03578224?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2018-09-06. Estimated completion is 2022-08-25.
What interventions are being tested in trial NCT03578224?
The interventions under investigation include: Contrast-Enhanced Ultrasound (PROCEDURE), Fine-Needle Aspiration (PROCEDURE), Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA) (PROCEDURE), Sonazoid (Perflubutane) (DRUG).
Who is sponsoring clinical trial NCT03578224?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.